Genta Inc. released the results from a pilot study on advanced melanoma incorporating the Company’s cancer drug Genasense(R) (oblimersen sodium). This study was featured earlier this week in a presentation at the World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers in Berlin, Germany, an international conference organized every year by a co-leader of the AGENDA trial, the European Association of Dermatologic Oncology (EADO).

Genasense, delivered for the first time in a high-dose, 1-hour intravenous (IV) format, was used along with the most common melanoma drug temozolomide (Temodar(R); Schering Plough, Inc.), and a paclitaxel suspension (Abraxane(R); Abraxis Bioscience, Inc.). Using a standard dose and schedule of Genasense, 500 mg over 24 hours for 7 days, showed good tolerability for 18 patients and was associated with clinical activity in prior results using this investigational combination of drugs.

Genasense, administered in this more aggressive schedule (1-hour IV twice a week for 4 weeks at 900 mg

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Tuesday November 17, 2009

DrStockPick.com Stock Report!

PWRM, NGSX

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

PWRM is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. PWRM’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). PWRM expects to complete phase II clinical validation trials of

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

DrStockPick.com Watch List!

My Picks for Tuesday November 17, 2009 are:

**************************************************************

NGSX, NeurogesX, Inc.

NGSX is a biopharmaceutical company focused on developing and commercializing novel pain management therapies.

** The U.S. Food and Drug Administration (FDA) has approved NGSX’s Qutenza(TM) (capsaicin) 8% patch, the first and only product containing prescription strength capsaicin, for the management of neuropathic pain due to postherpetic neuralgia, the nerve pain which can follow an attack of shingles.

NGSX’s Qutenza delivers a synthetic form of capsaicin, the substance in chili peppers that gives them their heat sensation, through a dermal delivery system, providing up to 12 weeks of reduced

...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Monday November 16, 2009

DrStockPick.com Stock Report!

**************************************************************

SNBP, Sinobiopharma Inc., SNBP.OB

SNBP is a fully integrated and highly innovative specialty biopharmaceutical company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world’s fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co., Ltd. in China, SNBP’s current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

SNBP reported that 23 generic drugs for which the Company has production rights are listed in China’s National Essential Drugs

...

Bristol-Myers Squibb Co. (BMY) intends to split its 83.1% holding in the Nutritional segment which operates under its subsidiary Mead Johnson and develops infant formulas such as Enfamil and other nutritional products. The move is aimed to enable the company to concentrate on its core biopharmaceutical business. The transaction is expected to be accretive to earnings beginning in 2010.  Under the terms of the deal, Bristol-Myers shareholders can exchange some, none or all of their shares of the company for shares of Mead Johnson common stock tax-free and at a discount. On completion, the exchange offer would enable Bristol-Myers to dispose of its entire holding interest in Mead Johnson.  For every $1 of Bristol-Myers stock exchanged, stockholders will get approximately $1.11 worth of Mead shares. The offer is set to expire on Dec 14, unless extended or terminated. Bristol-Myers owns 170 million shares of Mead Johnson. ...

Synergy Pharmaceuticals, Inc., a leading biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases, recently announced that the company has completed a private placement, raising an aggregate $8.6 million through the sale of common stock at a price of $0.70 per share.

The proceeds from the private placement will be used to fund a Phase IIa clinical trial of Synergy’s SP-304 for chronic constipation, which is scheduled to commence in the first quarter of 2010. SP-304, a synthetic analog of the human gastrointestinal hormone uroguanylin, recently finished a Phase I clinical trial in volunteers.

Mr. Gabriele Cerrone, chairman of Synergy Pharmaceuticals, stated, “This financing combined with the earlier financing we announced last summer of $7.09 million considerably strengthens our balance sheet, reflecting the strong continued interest in our drug candidate SP-304 to treat GI disorders.” Mr. Cerrone continued, “We believe that the market for GI

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

DrStockPick.com Watch List!

My Picks for Friday November 13, 2009 are:

**************************************************************

EMKR, EMCORE Corporation

EMKR provides compound semiconductor-based components and subsystems for the broadband, fiber optic, satellite, and terrestrial solar power markets. EMKR is the world’s largest manufacturer of highly efficient radiation hard solar cells for space power applications.

** EMKR has been awarded a contract by Dutch Space of Leiden, The Netherlands to manufacture, test, and deliver the solar panels to power the Cygnus’ spacecraft being developed by Orbital Sciences Corporation for NASA’s Commercial Resupply Service project.

The total value of the contract would be in excess of $15 million.

More about EMKR

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Monday November 2, 2009

DrStockPick.com Stock Report!

PWRM, AMLN

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete phase II clinical

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

DrStockPick.com Watch List!

My Picks for Monday November 2nd, 2009, are:

**************************************************************

AMLN, Amylin Pharmaceuticals, Inc.

AMLN is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines.

AMLN has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection.

The U.S. Food and Drug Administration (FDA) has approved an expanded indication for AMLN’s BYETTA® (exenatide) injection. BYETTA is now approved for use as a stand-alone medication (monotherapy) along with diet and exercise to improve glycemic control in adults with type 2 diabetes. Previously, it was approved for

...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Saturday October 31, 2009

DrStockPick.com Stock Report!

**************************************************************

AMLN, Amylin Pharmaceuticals, Inc.

AMLN is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines.

AMLN has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection.

The U.S. Food and Drug Administration (FDA) has approved an expanded indication for AMLN’s BYETTA® (exenatide) injection. BYETTA is now approved for use as a stand-alone medication (monotherapy) along with diet and exercise to improve glycemic control in adults with type

...